Tamoxifen Therapy for Retroperitoneal Fibrosis
Authors: Augusto Vaglio, Paolo Greco, Carlo Buzio
Journal: Annals of Internal Medicine (2006)

Letters18 April 2006Tamoxifen Therapy for Retroperitoneal FibrosisAugusto Vaglio, MD, Paolo Greco, MD, and Carlo Buzio, MDAugusto Vaglio, MDFrom University of Parma, 43100 Parma, Italy.Search for more papers by this author, Paolo Greco, MDFrom University of Parma, 43100 Parma, Italy.Search for more papers by this author, and Carlo Buzio, MDFrom University of Parma, 43100 Parma, Italy.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-144-8-200604180-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:On the basis of a series of 19 patients with nonmalignant retroperitoneal fibrosis (RPF), van Bommel and colleagues (1) suggest that tamoxifen may be an effective treatment option. Their study is a relevant contribution, mostly because the use of tamoxifen therapy for RPF had previously been described only in anecdotal case reports. However, a few points warrant discussion.The authors reported that RPF was idiopathic in 37% of their patients; in the remaining 63%, it was secondary to atherosclerosis (chronic periaortitis and perianeurysmal fibrosis) or recurrent pancreatitis. This description is somewhat unclear. Although there are no standardized ...References1. van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med. 2006;144:101-6. [PMID: 16418409] LinkGoogle Scholar2. Parums DV. The spectrum of chronic periaortitis. Histopathology. 1990;16:423-31. [PMID: 2193863] CrossrefMedlineGoogle Scholar3. Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet. 2006;367:241-51. [PMID: 16427494] CrossrefMedlineGoogle Scholar4. Vaglio A, Corradi D, Manenti L, Ferretti S, Garini G, Buzio C. Evidence of autoimmunity in chronic periaortitis: a prospective study. Am J Med. 2003;114:454-62. [PMID: 12727578] CrossrefMedlineGoogle Scholar5. Marcolongo R, Tavolini IM, Laveder F, Busa M, Noventa F, Bassi P, et al. Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med. 2004;116:194-7. [PMID: 14749165] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Augusto Vaglio, MD; Paolo Greco, MD; Carlo Buzio, MDAffiliations: From University of Parma, 43100 Parma, Italy.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoBrief Communication: Tamoxifen Therapy for Nonmalignant Retroperitoneal Fibrosis Eric F.H. van Bommel , Tadek R. Hendriksz , Antonius W.L.C. Huiskes , and Antoine G.M. Zeegers Tamoxifen Therapy for Retroperitoneal Fibrosis Eric F.H. van Bommel and Tadek R. Hendriksz Metrics Cited byIdiopathic and secondary forms of retroperitoneal fibrosis: A diagnostic approachTreatment of idiopathic retroperitoneal fibrosisTamoxifen Monotherapy in the Treatment of Retroperitoneal FibrosisMalignant Retroperitoneal Fibrosis 18 April 2006Volume 144, Issue 8Page: 619KeywordsAtherosclerosisAutoimmune diseasesConflicts of interestCorticosteroid therapyCreatinineFallsFibrosisImmunosuppressivesPancreatitisRenal failure ePublished: 18 April 2006 Issue Published: 18 April 2006 Copyright & PermissionsCopyright © 2006 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...